SpineGuard Revenue Drops 32% in H1 2026 Amid U.S. Business Model Shift
Event summary
- SpineGuard reported H1 2026 revenue of €1.45M, down 32% YoY from €2.12M in H1 2025.
- U.S. revenue fell 47% to $776K due to transition from direct sales to a distribution model with Omnia Medical.
- Europe grew 17%, while global unit sales declined 17% due to inventory effects from the U.S. shift.
- Company expects operating breakeven by Q4 2026 and has €763K cash position as of June 30, 2026.
The big picture
SpineGuard's revenue decline reflects strategic shifts in its U.S. operations, where it is transitioning to a distribution model to improve profitability per unit sold. The company positions its DSG technology as a cost-effective alternative to navigation systems and robots, targeting markets with limited adoption of high-cost solutions. Success will depend on executing this pivot while maintaining growth in Europe and expanding into new regions like China and the Middle East.
What we're watching
- Operational Breakeven
- Whether SpineGuard can achieve its target of operating breakeven by Q4 2026 amid revenue declines.
- U.S. Market Recovery
- The pace at which Omnia Medical's distribution model can drive sales growth in the U.S. market.
- International Expansion
- How SpineGuard will leverage strong European growth and emerging opportunities in China and Saudi Arabia.